Advanced search
Publication Cover
Clinical Toxicology Volume 56, 2018 - Issue 3
Submit an article Journal homepage
816
Views
16
CrossRef citations to date
0
Altmetric
Short Communications

Incomplete dabigatran reversal with idarucizumab

Aaron P. SteeleDepartment of Pharmacy Services, University of California, Davis Medical Center, Sacramento, CA, USAORCID Iconhttp://orcid.org/0000-0001-6689-050X
ORCID Icon,
Jin A. LeeDepartment of Pharmacy Services, University of California, Davis Medical Center, Sacramento, CA, USA
&
William E. DagerDepartment of Pharmacy Services, University of California, Davis Medical Center, Sacramento, CA, USACorrespondence[email protected]
Pages 216-218 | Received 28 Apr 2017, Accepted 29 Jun 2017, Published online: 13 Jul 2017

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Akshay Athavale, Nazila Jamshidi & Darren M. Roberts. (2020) Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. Clinical Toxicology 58:8, pages 789-800.
Read now

Articles from other publishers (15)

Richard H. ParrishIIII, Heather Monk Bodenstab, Dustin Carneal, Ryan M. Cassity, William E. Dager, Sara J. Hyland, Jenna K. Lovely, Alyssa Pollock, Tracy M. Sparkes & Siu-Fun Wong. (2022) Positive Patient Postoperative Outcomes with Pharmacotherapy: A Narrative Review including Perioperative-Specialty Pharmacist Interviews. Journal of Clinical Medicine 11:19, pages 5628.
Crossref
Sara Kutner, Nicholas Scaturo & Brett Williams. (2021) Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).. The American Journal of Emergency Medicine 46, pages 800.e1-800.e3.
Crossref
David B. Liss & Michael E. Mullins. (2021) Antithrombotic and Antiplatelet Drug Toxicity. Critical Care Clinics 37:3, pages 591-604.
Crossref
Sonal Singh, Amit Nautiyal & Kathy W. Belk. (2019) Real World Outcomes Associated with Idarucizumab: Population-Based Retrospective Cohort Study. American Journal of Cardiovascular Drugs 20:2, pages 161-168.
Crossref
Shusuke Takeshita, Kenichi A. Tanaka, Teiji Sawa, Masashi Sanda, Toshiki Mizobe & Satoru Ogawa. (2020) Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran. Anesthesia & Analgesia 130:2, pages 535-541.
Crossref
Rahul Chaudhary, Tushar Sharma, Jalaj Garg, Ajaypaul Sukhi, Kevin Bliden, Udaya Tantry, Mohit Turagam, Dhanunjaya Lakkireddy & Paul Gurbel. (2019) Direct oral anticoagulants: a review on the current role and scope of reversal agents. Journal of Thrombosis and Thrombolysis 49:2, pages 271-286.
Crossref
Stephanie Kustos & Pius Fasinu. (2019) Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update. Medicines 6:4, pages 103.
Crossref
Victor M. Lu, Kevin Phan, Prashanth J. Rao, Sunjay V. Sharma & Ekkehard M. Kasper. (2019) Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature. Clinical Neurology and Neurosurgery 181, pages 76-81.
Crossref
Lucy McBride, Julie Wang, Prahlad Ho & David Langsford. (2019) Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required. Kidney International Reports 4:3, pages 500-504.
Crossref
W.E. Dager, A.J. Roberts & D.K. Nishijima. (2019) Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Thrombosis Research 173, pages 71-76.
Crossref
Olga O. Shakhmatova. (2018) IDARUCIZUMAB, A SPECIFIC REVERSAL AGENT FOR DABIGATRAN: THE PRESENT-DAY KNOWLEDGE. Atherothrombosis Journal:2, pages 147-157.
Crossref
Drayton A. Hammond, Laura Baumgartner, Craig Cooper, Elisabeth Donahey, Serena A. Harris, Jessica M. Mercer, Mandy Morris, Mona K. Patel, Angela M. Plewa-Rusiecki, Alia A. Poore, Ryan Szaniawski & Deanna Horner. (2018) Major publications in the critical care pharmacotherapy literature: January–December 2017. Journal of Critical Care 45, pages 239-246.
Crossref
Joseph R. Shaw & Deborah M. Siegal. (2018) Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature. Research and Practice in Thrombosis and Haemostasis 2:2, pages 251-265.
Crossref
. (2018) Dabigatran etexilate overdose. Reactions Weekly 1690:1, pages 77-77.
Crossref
Joseph Ebinger, Christopher B. Granger, Alexander Zhu, Allison Chang & Timothy D. Henry. (2017) Idarucizumab since FDA approval: Use in the real-world. American Heart Journal 193, pages 93-94.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.